Lilly Not Ducking M&A, But Will Play To Strengths In Cancer And Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
The Indiana-based big pharma will focus on product-level acquisitions in its core areas of strengths now that it has rounded out its animal health business with its $5.4 billion acquisition of Novartis Animal Health.
You may also be interested in...
Emerging Markets Earnings Roundup: Eli Lilly (Part 6)
China and emerging markets are expected to come to the fore for Eli Lilly as it works through patent expirations in the United States, while Japan helped despite a weaker yen.
Pfizer’s Latest Palbociclib Data Could Mean Slimmer Lead Over CDK4/6 Rivals
Final Phase II data for palbociclib in breast cancer at AACR meeting raise questions about prospects for accelerated approval prior to Phase III results. Meanwhile, Lilly’s bemaciclib emerges as potent monotherapy with seemingly lower risk for neutropenia, but more data are needed to flesh out the drug’s profile.
Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin
Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.